Charleston News Online

Liquid Biopsy for Cancer Diagnostics is Booming Worldwide with Prominent Player – Guardant Health, Roche, Neo Genomics, Qiagen, ArcherDX, Bio-Techne & Others | Delveinsight

Liquid Biopsy for Cancer Diagnostics is Booming Worldwide with Prominent Player – Guardant Health, Roche, Neo Genomics, Qiagen, ArcherDX, Bio-Techne & Others | Delveinsight

May 27
20:06 2021
Liquid Biopsy for Cancer Diagnostics is Booming Worldwide with Prominent Player - Guardant Health, Roche, Neo Genomics, Qiagen, ArcherDX, Bio-Techne & Others | Delveinsight

Liquid Biopsy for Cancer Diagnostics

DelveInsight’s Liquid Biopsy for Cancer Diagnostics Competitive Landscape and Pipeline Analysis provides the competitive analysis of both the marketed and the pipeline devices in the area of Liquid Biopsy for Cancer Diagnostics and comprises of market dynamics and key competitors of Liquid Biopsy for Cancer Diagnostics devices.

 

Key Competitors in Liquid Biopsy for Cancer Diagnostics Pipeline and Market

  • Guardant Health
  • Roche
  • Neo Genomics
  • Qiagen
  • ArcherDX
  • Bio-Techne
  • Resolution Bioscience
  • Personal Genome Diagnostics
  • Laboratory for Advanced Medicine (LAM)
  • Lucence Diagnostics
  • Foundation Medicine Inc
  • Biocept
  • Sysmex Ionostics Inc
  • Veridex LLC (Janssen Diagnostics)
  • Biodesix
  • Pathway Genomics
  • Exact Sciences
  • Angle Plc
  • GRAIL Inc.
  • NuProbe
  • OncoCell MDx Inc
  • Merck
  • AmoyDx

 

Know more about the key companies involved @ https://www.delveinsight.com/sample-request/liquid-biopsy-for-cancer-diagnostics-pipeline-insight

 

Key Highlights of Liquid Biopsy for Cancer Diagnostics Competitive Landscape and Pipeline report

  • According to DelveInsight’s competitive analysis, the emerging Liquid Biopsy tests for cancer diagnostics occupy a substantial share of about 79%, whereas the marketed liquid biopsy tests account for about 21% only.
  • Liquid Biopsy is a revolutionary technique that consists of the detection and isolation of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and exosomes, as a source of genomic and proteomic information in patients with cancer. The significant advantages of liquid Biopsy in cancer diagnosis are that the technique is minimally invasive, painless, does not have a risk of complications, and gives faster results as compared to tumor biopsies.
  • According to Delveinsight’s competitive analysis done by different indications, the non-small cell lung carcinoma occupy a large share of about 26% alone, whereas the rest of the indications (such as breast, liver, prostate cancers, among others) occupy a much smaller percentage.
  • The developments that have taken place in the field of liquid diagnostics comprise of the next-generation sequencing panel: (NuProbe), Liquid Biopsy Test for Prostate Cancer: (OncoCell MDx Inc.) and Liquid biopsy RAS biomarker test: (Merck/AmoyDx); these tests are still in very initial phases and have not yet entered their developmental phase.

 

Request a sample @ https://www.delveinsight.com/sample-request/liquid-biopsy-for-cancer-diagnostics-pipeline-insight

 

Liquid Biopsy for Cancer Diagnostics Competitive Landscape and Pipeline Insights

Cancer is among the leading causes of death worldwide. According to the National Cancer Institute, the number of new cases per year is expected to rise to 23.6 million by 2030. With this growing prevalence of cancer, there is a need to control it through proper diagnoses and testing. Liquid Biopsy helps utilize circulating biomarkers in the body fluids of cancer patients to provide information regarding the genetic landscape of cancer. It is emerging as a new tool to help in the early detection of cancer.

Various pharmaceutical companies are developing assays, which are marketed such as Guardant360 CDx assay, Cobas EGFR Mutation Test v2, InVisionFirst, Therascreen PIK3CA test, ArcherMET, ExoDx Prostate Test, Resolution ctDx Lung assay, PlasmaSELECT 64, IvyGene DX Liver Cancer Test, LiquidHallmark test, FoundationOne Liquid, OncoBEAM, among others and some of which are in the pipeline such as  CancerIntercept Detect, Exact Science’s DNA methylation-based liquid biopsy test, Parsortix, Grail’s liquid biopsy cancer test are expected to enter the market by 2026 as effective therapies.

 

Request for free sample report @ https://www.delveinsight.com/sample-request/liquid-biopsy-for-cancer-diagnostics-pipeline-insight

 

Table of Content

1

Key Insights

2

Executive Summary of Liquid Biopsy for Cancer Diagnostics

3

Liquid Biopsy for Cancer Diagnostics: Background and Overview

4

Liquid Biopsy Devices: Marketed Products

5

Liquid Biopsy Devices: Pipeline Products

6

Liquid Biopsy for Cancer Diagnostics: Other Developments

7

Liquid Biopsy for Cancer Diagnostics: Competitive Analysis

8

Liquid Biopsy for Cancer Diagnostics: Analytical Perspective